Growth Differentiation Factor-15: A Novel Biomarker for Predicting Risk of Venous Thromboembolism and Bleeding in Patients with Cancer

Thromb Haemost 2022; 122(07): 1075
DOI: 10.1055/a-1827-7328

Invited T&H Insights

Stephan Nopp

¹Clinical Division of Hematology and Hemostaseology, Department of Medicine I, Medical University of Vienna, Vienna, Austria

,

Ingrid Pabinger

¹Clinical Division of Hematology and Hemostaseology, Department of Medicine I, Medical University of Vienna, Vienna, Austria

References
1 Grilz E, Posch F, Nopp S. et al. Relative risk of arterial and venous thromboembolism in persons with cancer vs. persons without cancer-a nationwide analysis. Eur Heart J 2021; 42 (23) 2299-2307
2 Roy DC, Wang T-F, Mallick R. et al. Growth differentiation factor-15, high-sensitivity cardiac troponin T, and N-terminal pro-B-type natriuretic peptide for predicting risk of venous thromboembolism in ambulatory cancer patients receiving chemotherapy. Thromb Haemost 2022; 122 (05) 1169-1176
3 Mulder FI, Bosch FTM, Carrier M. et al. Growth differentiation factor-15 for prediction of bleeding in cancer patients. J Thromb Haemost 2022; 20 (01) 138-144